Sixty Degree Capital is a Toronto-based venture capital firm founded in 2017 that manages over $620 million. See sector focus, stage focus and contact routes.
Sixty Degree Capital is a Toronto-based venture capital firm founded in 2017 that manages over $620 million in assets under management and has completed more than 60 investments with 12+ successful exits[1][3]. The firm invests across pre-seed to growth stages in technology sectors including AI, cybersecurity, digital infrastructure, and SaaS, as well as healthcare areas such as drug development, diagnostics, digital health, and medical devices[3][7]. Typical check sizes range from $1 million to $10 million, and the firm operates with a global mandate while currently focusing primarily on the US market[4][7]. Notable portfolio companies include Eclypsium, which received a Series C investment from the firm in September 2024, and Korro Bio, which was among their latest exits in November 2023[13]. The firm also participated in the 2023 acquisition of CinCor Pharma by AstraZeneca, one of its 12+ documented exits[7]. Sixty Degree Capital distinguishes itself through a thesis-building approach backed by fundamental research and collaboration with a deep advisor network to select high-return companies[11].
This profile is part of the StartupFundraising firm database: focus, portfolio history, disclosed location and contact routes, refreshed as new filings and rounds are ingested. Founders use it to check fit before reaching out and to find comparable investors.
Investors like Sixty Degree Capital · Full investor directory · Investor access · Company funding database